Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. (Q38794688)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 March 2016

Language	Label	Description	Also known as
English	Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.	scientific article published on 28 March 2016

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

inflammatory breast cancer

1 reference

based on heuristic

inferred from title

Christelle Levy

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Philippe Barthélémy

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Emmanuelle Charafe-Jauffret

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

François-Clément Bidard

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Thomas Bachelot

13

object named as

Thomas Bachelot

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

author name string

François Bertucci

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Mahmoud Fekih

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Aurélie Autret

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Thierry Petit

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Florence Dalenc

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Gilles Romieu

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Jacques Bonneterre

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Jean-Marc Ferrero

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Pierre Kerbrat

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Patrick Soulie

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Marie-Ange Mouret-Reynier

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Florence Lerebours

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Jean-Christophe Eymard

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Mathilde Deblock

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Alain Lortholary

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Anne-Claire Hardy-Bessard

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Hervé Bonnefoi

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Jérôme Lemonnier

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Jean-Yves Pierga

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

publication date

28 March 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

600-611

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel in the multimodality treatment for inflammatory breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the molecular biology of inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular targets for treatment of inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A systematic review of bevacizumab efficacy in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900011-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)00011-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27032301%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38794688&oldid=2104629392"